- Home
- FMAO vs GOSS Comparison
FMAO vs GOSS Comparison
Compare FMAO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- GOSS
- Stock Information
- Founded
- FMAO 1897
- GOSS 2015
- Country
- FMAO United States
- GOSS United States
- Employees
- FMAO N/A
- GOSS N/A
- Industry
- FMAO Savings Institutions
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- GOSS Health Care
- Exchange
- FMAO Nasdaq
- GOSS Nasdaq
- Market Cap
- FMAO 356.9M
- GOSS 347.8M
- IPO Year
- FMAO N/A
- GOSS 2019
- Fundamental
- Price
- FMAO $26.13
- GOSS $2.47
- Analyst Decision
- FMAO
- GOSS Strong Buy
- Analyst Count
- FMAO 0
- GOSS 4
- Target Price
- FMAO N/A
- GOSS $8.50
- AVG Volume (30 Days)
- FMAO 21.8K
- GOSS 3.1M
- Earning Date
- FMAO 10-29-2025
- GOSS 08-05-2025
- Dividend Yield
- FMAO 3.34%
- GOSS N/A
- EPS Growth
- FMAO 38.39
- GOSS N/A
- EPS
- FMAO 2.16
- GOSS N/A
- Revenue
- FMAO $108,632,000.00
- GOSS $40,237,000.00
- Revenue This Year
- FMAO $1.60
- GOSS N/A
- Revenue Next Year
- FMAO $13.77
- GOSS $30.65
- P/E Ratio
- FMAO $12.26
- GOSS N/A
- Revenue Growth
- FMAO 13.86
- GOSS N/A
- 52 Week Low
- FMAO $20.88
- GOSS $0.66
- 52 Week High
- FMAO $34.15
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- FMAO 58.09
- GOSS 68.08
- Support Level
- FMAO $24.60
- GOSS $2.38
- Resistance Level
- FMAO $27.01
- GOSS $2.65
- Average True Range (ATR)
- FMAO 0.81
- GOSS 0.15
- MACD
- FMAO 0.23
- GOSS 0.03
- Stochastic Oscillator
- FMAO 89.44
- GOSS 76.67
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.